Ed Arce
Stock Analyst at HC Wainwright & Co.
(3.07)
# 1,255
Out of 4,502 analysts
332
Total ratings
40%
Success rate
1.55%
Average return
Main Sectors:
Top Industries:
35 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MIRM Mirum Pharmaceuticals | Reiterates: Buy | $66 | $40.37 | +63.49% | 27 | Jul 26, 2024 | |
| PLRX Pliant Therapeutics | Reiterates: Buy | $36 | $13.31 | +170.47% | 17 | Jul 16, 2024 | |
| UNCY Unicycive Therapeutics | Reiterates: Buy | $4.5 | $0.44 | +922.73% | 18 | Jul 10, 2024 | |
| ARCT Arcturus Therapeutics Holdings | Reiterates: Buy | $60 | $22.98 | +161.10% | 18 | Jul 2, 2024 | |
| ITRM Iterum Therapeutics | Reiterates: Buy | $6 | $1.25 | +380.00% | 10 | Jun 21, 2024 | |
| ASMB Assembly Biosciences | Reiterates: Neutral | n/a | $14.84 | - | 5 | Jun 20, 2024 | |
| SGMT Sagimet Biosciences | Reiterates: Buy | $32 | $3.40 | +841.18% | 5 | Jun 14, 2024 | |
| GNFT Genfit | Maintains: Buy | $11 → $13 | $4.52 | +187.61% | 13 | Jun 11, 2024 | |
| ETNB 89bio | Reiterates: Buy | $29 | $9.66 | +200.21% | 18 | Jun 11, 2024 | |
| AKRO Akero Therapeutics | Reiterates: Buy | $50 | $28.32 | +76.55% | 16 | Jun 11, 2024 | |
| ABUS Arbutus Biopharma | Reiterates: Buy | $5 | $3.92 | +27.55% | 15 | Jun 7, 2024 | |
| DRRX DURECT | Reiterates: Neutral | n/a | $1.65 | - | 9 | May 22, 2024 | |
| ACXP Acurx Pharmaceuticals | Reiterates: Buy | $12 | $2.26 | +430.97% | 11 | May 16, 2024 | |
| TLPH Talphera | Reiterates: Buy | $6 | $0.88 | +579.58% | 3 | May 15, 2024 | |
| TERN Terns Pharmaceuticals | Reiterates: Neutral | $5.5 | $8.79 | -37.43% | 9 | May 14, 2024 | |
| MDGL Madrigal Pharmaceuticals | Maintains: Buy | $425 → $390 | $283.46 | +37.59% | 12 | May 8, 2024 | |
| TVTX Travere Therapeutics | Reiterates: Buy | $19 | $9.77 | +94.47% | 16 | May 7, 2024 | |
| ENTA Enanta Pharmaceuticals | Maintains: Buy | $28 → $27 | $15.33 | +76.13% | 7 | May 7, 2024 | |
| GALT Galectin Therapeutics | Reiterates: Buy | $11 | $2.55 | +331.37% | 9 | Apr 9, 2024 | |
| CDTX Cidara Therapeutics | Maintains: Buy | $120 | $11.95 | +904.18% | 17 | Apr 8, 2024 | |
| IVA Inventiva | Reiterates: Buy | $22 | $2.28 | +864.91% | 11 | Apr 1, 2024 | |
| AKBA Akebia Therapeutics | Maintains: Buy | $5 → $6 | $1.48 | +305.41% | 20 | Mar 28, 2024 | |
| ZVSA ZyVersa Therapeutics | Reiterates: Buy | $240 | $3.85 | +6,133.77% | 4 | Mar 26, 2024 | |
| SYBX Synlogic | Upgrades: Neutral | n/a | $1.68 | - | 8 | Mar 20, 2024 | |
| AUPH Aurinia Pharmaceuticals | Reiterates: Buy | $13 | $5.60 | +132.14% | 11 | Mar 1, 2024 | |
| VERA Vera Therapeutics | Reiterates: Buy | $25 | $36.84 | -32.14% | 7 | Dec 27, 2023 | |
| ARDX Ardelyx | Maintains: Buy | $9 → $11 | $5.49 | +100.36% | 3 | Nov 1, 2023 | |
| RARE Ultragenyx Pharmaceutical | Reiterates: Buy | $82 | $45.06 | +81.98% | 2 | Aug 1, 2023 | |
| GLMD Galmed Pharmaceuticals | Downgrades: Neutral | n/a | $0.31 | - | 2 | May 3, 2022 | |
| ATXI Avenue Therapeutics | Maintains: Buy | $13,500 → $14,625 | $2.87 | +509,481.88% | 2 | May 12, 2020 | |
| SMMT Summit Therapeutics | Initiates: Buy | n/a | $10.49 | - | 1 | Mar 19, 2020 | |
| TRVN Trevena | Downgrades: Neutral | n/a | $0.23 | - | 3 | Nov 5, 2018 | |
| VKTX Viking Therapeutics | Assumes: Buy | n/a | $64.68 | - | 1 | Nov 10, 2017 | |
| COLL Collegium Pharmaceutical | Initiates: Buy | n/a | $35.42 | - | 1 | Sep 11, 2017 | |
| AVIR Atea Pharmaceuticals | Downgrades: Neutral | n/a | $3.90 | - | 1 | Feb 15, 2017 |
Mirum Pharmaceuticals
Jul 26, 2024
Reiterates: Buy
Price Target: $66
Current: $40.37
Upside: +63.49%
Pliant Therapeutics
Jul 16, 2024
Reiterates: Buy
Price Target: $36
Current: $13.31
Upside: +170.47%
Unicycive Therapeutics
Jul 10, 2024
Reiterates: Buy
Price Target: $4.5
Current: $0.44
Upside: +922.73%
Arcturus Therapeutics Holdings
Jul 2, 2024
Reiterates: Buy
Price Target: $60
Current: $22.98
Upside: +161.10%
Iterum Therapeutics
Jun 21, 2024
Reiterates: Buy
Price Target: $6
Current: $1.25
Upside: +380.00%
Assembly Biosciences
Jun 20, 2024
Reiterates: Neutral
Price Target: n/a
Current: $14.84
Upside: -
Sagimet Biosciences
Jun 14, 2024
Reiterates: Buy
Price Target: $32
Current: $3.40
Upside: +841.18%
Genfit
Jun 11, 2024
Maintains: Buy
Price Target: $11 → $13
Current: $4.52
Upside: +187.61%
89bio
Jun 11, 2024
Reiterates: Buy
Price Target: $29
Current: $9.66
Upside: +200.21%
Akero Therapeutics
Jun 11, 2024
Reiterates: Buy
Price Target: $50
Current: $28.32
Upside: +76.55%
Arbutus Biopharma
Jun 7, 2024
Reiterates: Buy
Price Target: $5
Current: $3.92
Upside: +27.55%
DURECT
May 22, 2024
Reiterates: Neutral
Price Target: n/a
Current: $1.65
Upside: -
Acurx Pharmaceuticals
May 16, 2024
Reiterates: Buy
Price Target: $12
Current: $2.26
Upside: +430.97%
Talphera
May 15, 2024
Reiterates: Buy
Price Target: $6
Current: $0.88
Upside: +579.58%
Terns Pharmaceuticals
May 14, 2024
Reiterates: Neutral
Price Target: $5.5
Current: $8.79
Upside: -37.43%
Madrigal Pharmaceuticals
May 8, 2024
Maintains: Buy
Price Target: $425 → $390
Current: $283.46
Upside: +37.59%
Travere Therapeutics
May 7, 2024
Reiterates: Buy
Price Target: $19
Current: $9.77
Upside: +94.47%
Enanta Pharmaceuticals
May 7, 2024
Maintains: Buy
Price Target: $28 → $27
Current: $15.33
Upside: +76.13%
Galectin Therapeutics
Apr 9, 2024
Reiterates: Buy
Price Target: $11
Current: $2.55
Upside: +331.37%
Cidara Therapeutics
Apr 8, 2024
Maintains: Buy
Price Target: $120
Current: $11.95
Upside: +904.18%
Inventiva
Apr 1, 2024
Reiterates: Buy
Price Target: $22
Current: $2.28
Upside: +864.91%
Akebia Therapeutics
Mar 28, 2024
Maintains: Buy
Price Target: $5 → $6
Current: $1.48
Upside: +305.41%
ZyVersa Therapeutics
Mar 26, 2024
Reiterates: Buy
Price Target: $240
Current: $3.85
Upside: +6,133.77%
Synlogic
Mar 20, 2024
Upgrades: Neutral
Price Target: n/a
Current: $1.68
Upside: -
Aurinia Pharmaceuticals
Mar 1, 2024
Reiterates: Buy
Price Target: $13
Current: $5.60
Upside: +132.14%
Vera Therapeutics
Dec 27, 2023
Reiterates: Buy
Price Target: $25
Current: $36.84
Upside: -32.14%
Ardelyx
Nov 1, 2023
Maintains: Buy
Price Target: $9 → $11
Current: $5.49
Upside: +100.36%
Ultragenyx Pharmaceutical
Aug 1, 2023
Reiterates: Buy
Price Target: $82
Current: $45.06
Upside: +81.98%
Galmed Pharmaceuticals
May 3, 2022
Downgrades: Neutral
Price Target: n/a
Current: $0.31
Upside: -
Avenue Therapeutics
May 12, 2020
Maintains: Buy
Price Target: $13,500 → $14,625
Current: $2.87
Upside: +509,481.88%
Summit Therapeutics
Mar 19, 2020
Initiates: Buy
Price Target: n/a
Current: $10.49
Upside: -
Trevena
Nov 5, 2018
Downgrades: Neutral
Price Target: n/a
Current: $0.23
Upside: -
Viking Therapeutics
Nov 10, 2017
Assumes: Buy
Price Target: n/a
Current: $64.68
Upside: -
Collegium Pharmaceutical
Sep 11, 2017
Initiates: Buy
Price Target: n/a
Current: $35.42
Upside: -
Atea Pharmaceuticals
Feb 15, 2017
Downgrades: Neutral
Price Target: n/a
Current: $3.90
Upside: -